A Phase 1, Open-Label, Multicenter, Dose Escalation and Expansion Study of PRT811 in Subjects With Advanced Solid Tumors, CNS Lymphoma, and Recurrent High-Grade Gliomas

This is a Phase 1 dose-escalation study of PRT811, a protein arginine N-methyltransferase (PRMT) 5 inhibitor, in subjects with advanced cancers and high-grade gliomas who have exhausted available treatment options. The purpose of this study is to define a safe dose and schedule to be used in subsequent development of PRT811.

开始日期2019-11-06

申办/合作机构

Prelude Therapeutics, Inc.

100 项与 PRT-811 相关的临床结果

登录后查看更多信息

100 项与 PRT-811 相关的转化医学

登录后查看更多信息

100 项与 PRT-811 相关的专利（医药）

登录后查看更多信息

项与 PRT-811 相关的文献（医药）

2022-08-01·Journal of immunotherapy and precision oncology

Protein Arginine Methyltransferase 5 (PRMT5) Inhibitors in Oncology Clinical Trials: A review

Review

作者: Feustel, Kavanya ; Falchook, Gerald S.

ABSTRACT:

Protein arginine methyltransferase 5 (PRMT5) inhibitors are a new class of antineoplastic agents showing promising preliminary clinical efficacy. Targeting an enzyme involved in a wide array of cellular and transcriptional pro-oncogenic processes, this class offers multifaceted tumor-suppressive effects. Partial response has been seen in adenoid cystic carcinoma from both GSK3326595 and JNJ-64619178, with four cases of stable disease seen with PRT543. Highly significant is a durable complete response in isocitrate dehydrogenase 1-mutated glioblastoma multiforme with PRT811. Both alone and in combination with existing chemotherapies and immunotherapies, this class shows promising preliminary data, particularly in cancers with splicing mutations and DNA damage repair deficiencies. Further studies are warranted, and there are clinical trials to come whose data will be telling of the efficacy of PRMT5 inhibitors in both hematologic and solid malignancies. The aim of this study is to compile available results of PRMT5 inhibitors in oncology clinical trials.

2020-10-01·Journal of biomedical materials research. Part B, Applied biomaterials3区 · 工程技术

Comparison of two pore sizes of LAE442 scaffolds and their effect on degradation and osseointegration behavior in the rabbit model

3区 · 工程技术

Article

作者: Feichtner, Franziska ; Maier, Hans Jürgen ; Wriggers, Peter ; Waselau, Anja‐Christina ; Julmi, Stefan ; Meyer‐Lindenberg, Andrea ; Augustin, Julia ; Klose, Christian

Abstract:

The magnesium alloy LAE442 emerged as a possible bioresorbable bone substitute over a decade ago. In the present study, using the investment casting process, scaffolds of the Magnesium (Mg) alloy LAE442 with two different and defined pore sizes, which had on average a diameter of 400 μm (p400) and 500 μm (p500), were investigated to evaluate degradation and osseointegration in comparison to a ß‐TCP control group. Open‐pored scaffolds were implanted in both greater trochanter of rabbits. Ten scaffolds per time group (6, 12, 24, and 36 weeks) and type were analyzed by clinical, radiographic and μ‐CT examinations (2D and 3D). None of the scaffolds caused adverse reactions. LAE442 p400 and p500 developed moderate gas accumulation due to the Mg associated in vivo corrosion, which decreased from week 20 for both pore sizes. After 36 weeks, p400 and p500 showed volume decreases of 15.9 and 11.1%, respectively, with homogeneous degradation, whereas ß‐TCP lost 74.6% of its initial volume. Compared to p400, osseointegration for p500 was significantly better at week 2 postsurgery due to more frequent bone‐scaffold contacts, higher number of trabeculae and higher bone volume in the surrounding area. No further significant differences between the two pore sizes became apparent. However, p500 was close to the values of ß‐TCP in terms of bone volume and trabecular number in the scaffold environment, suggesting better osseointegration for the larger pore size.

2016-04-01·Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban

Efficacy of different fluids preload on propofol injection pain: A randomized, controlled, double-blinded study

Article

作者: Yuan, Shi-Ying ; Luo, Tian-Yuan ; Liu, Zhen ; Lin, Yun

Injection pain of propofol remains a common clinical problem. Previous studies demonstrated that propofol injection pain was alleviated by applying nitroglycerin ointment to the skin of injection site, which inspires us to test whether venous vasodilation induced by fluid preload could alleviate the pain. Different types or volumes of fluid preload were compared. 200 ASA I-II adult patients were randomly assigned to five groups of 40 each. A 20 G cannula was established on the dorsum or wrist of the hand. When fluid preload given with Plasma-Lyte A 100 mL (P100 group), 250 mL (P250 group), 500 mL (P500 group), 0.9% saline 500 mL (N500 group) or Gelofusine 500 mL (G500 group) was completed within 30 min, respectively, Propofol (0.5 mg/kg, 1%) was injected at a rate of 0.5 mL/s. A blind investigator assessed the pain using a four-point scale. Incidence of pain in P100, P250, and P500 groups was 87.5%, 57.5% and 35%, respectively (P<0.05). The median pain intensity score was significantly lower in P500 group than that in P250 and P100 groups (P<0.05 and P<0.01, respectively). Comparison of the effect of different types of solution preload indicated that the highest incidence of pain was in N500 group (62.5%) (N500 vs. P500, P=0.014; N500 vs. G500, P=0.007). The median pain intensity score in N500 group was higher than that in P500 group (P<0.05) and G500 group (P<0.05). There was no significant difference between P500 and G500 groups. It is suggested that Plasma-Lyte A or Gelofusine preload with 500 mL before propofol injection is effective in alleviating propofol-induced pain.

项与 PRT-811 相关的新闻（医药）

2025-07-30

·BioSpace

The Top Five Biopharma Venture Capital Raises of H1, 2025

iStock, Velishchuk Though nerves abound for funders and founders in the industry, money continues to flow into startups, sometimes in eye-popping numbers. BioSpace rounds up the biggest raises so far this year. Financing across the biopharmaceutical industry is at a painful crawl. Nowhere is this clearer than in the venture capital realm. Research from Citeline and Pitchbook showed that VC fundraising for biopharmas has been dropping for four straight quarters and has generally been trending downward since the pandemic-induced rush of money into the industry in 2021. However, some firms are still managing to scare up large venture rounds in 2025, and series A and series B funding rounds are ticking up, according to a report from biopulse . Research from PitchBook shows that though the number of raises and the total amount raised fell slightly in Q2 2025, for the past five quarters it has held steady at around $8 billion–$9 billion per quarter. Here BioSpace recaps the biggest raises of the year so far, all of which fall into hot research areas such as AI and obesity. Isomorphic Labs Amount raised: $600 million Disease area: Not disclosed The biggest raise of the first half of the year went to Isomorphic Labs, a spinout of Google’s DeepMind division that garnered $600 million in March to create new AI-designed drugs. Although the company has no published pipeline and hasn’t announced any disease targets, only mentioning “challenging disease areas” in a blog post , the company expects to start clinical trials for newly discovered molecules by the end of 2025 . Isomorphic has already bagged big partnerships with Eli Lilly and Novartis that together total nearly $ 3 billion in biobucks. Now valued at nearly $1.8 billion, the company is one of a handful of biotech unicorns , all of which are built on AI. Verdiva Bio Amount raised: $411 million Disease area: Obesity and metabolism While pharma giants like Novo Nordisk and Eli Lilly are leading the obesity field, a suite of smaller companies are betting on next-generation therapies to get ahead of the curve. Right around the time of the JP Morgan Conference in January, Verdiva Bio joined them with a $411 million series A . That money is going toward a pipeline of obesity drugs formulations licensed from the Chinese biotech Sciwind Biosciences. That includes an oral, once-per-week GLP-1 drug, as well as two amylin assets, one administered orally and one subcutaneously. Pathos AI Amount raised: $365 million Disease area: Prostate cancer and other tumor types Following Isomorphic Labs’ gargantuan raise, Pathos, another AI-powered biopharma startup, got a $365 million series D in May to continue developing its oncology pipeline, bringing its total capital raised to $1.6 billion. Despite being an AI-focused company, its lead asset, pocenbrodib, was licensed from Novo Nordisk, which got it from Forma Therapeutics. Pocenbrodib is currently in a Phase Ib/IIa trial for patients with metastatic castration-resistant prostate cancer. Another molecule the company is pursuing is P-500, a brain-penetrant drug licensed from Prelude Therapeutics for treating brain cancers. Eikon Therapeutics Amount raised: $351 million Disease areas: Several, including cancer, inflammation and neurological diseases Eikon, another biotech unicorn with a valuation of $1.85 billion, added a $351 million series D to an already impressive funding haul in February . The new money is going towards EIK1001, a Toll-like receptor agonist for treating advanced melanoma. Eikon showed off some preliminary results at the American Society of Clinical Oncology annual meeting last year, including a 14% complete or partial response rate. According to CEO Roger Perlmutter, the company has its eye on an eventual IPO. Numab Therapeutics Amount raised: $227 million Disease areas: Immunology and cancer using multispecific antibodies Founded back in 2011, in January Numab grabbed an extra $55 million in an extended series C, bringing the total raise for the round to about $227 million. That adds to an already significant ledger after Numab spun off NM26, an investigational bi-specific antibody for atopic dermatitis, into a new company called Yellow Jersey Therapeutics and then sold Yellow Jersey to Johnson & Johnson in 2024 for $1.25 billion. The new raise is going toward furthering the company’s inflammation and oncology pipeline, including its lead asset, NM32, a T cell engager for solid tumors and hematological cancers.

上市批准

2025-07-17

·动脉网

3.65亿美元融资：这家AI制药大模型公司合作阿斯利康、引入外部管线

近日，生物技术公司Pathos AI宣布完成3.65亿美元的D轮融资，融资后估值约为16亿美元。本轮资金将用于支持公司临床阶段产品线的推进，并持续投资于其专为肿瘤学构建的专有人工智能基础模型。在AI大模型加速渗透医疗领域、众多企业纷纷布局制药大模型的当下，Pathos的核心竞争力究竟体现在哪些方面？我们来一一解码。01锚定肿瘤药物开发赛道，利用AI驱动创新药临床加速Pathos创立于2020年，总部位于美国纽约，是一家专注于人工智能驱动药物开发的生物科技公司，特别是针对肿瘤治疗。领导团队具有鲜明的跨学科特色，成员专业背景横跨多领域，为研究提供了多维度的思考视角和专业互补优势。首席执行官Iker Huerga，拥有超20年机器学习与肿瘤学交叉领域经验，曾任阿斯利康肿瘤学研发首席数据科学家、Tempus Labs执行副总裁，创立过多家AI驱动肿瘤学初创公司，专注于多模式AI在临床试验与精准医疗中的应用。首席医疗官Jens Renstrup博士与首席科学官是医学/ MBA双学位博士，拥有超过25年的全球制药和生物技术行业经验，曾任Springworks Therapeutics首席医疗官、Alexion Pharmaceuticals全球医疗事务主管，深耕肿瘤药物开发及跨治疗领域管线推进。首席科学官Eric Schadt是生物数学博士，曾任Sema4创始CEO、西奈山伊坎医学院基因组学系主任，曾主导超大规模数据的计算生物学方法开发。首席执行官Iker Huerga（左）首席医疗官Jens Renstrup（中）首席科学官Eric Schadt（右）来自：Pathos官网Pathos自成立以来，凭借在AI驱动肿瘤药物研发领域的创新探索，吸引了大量资本关注，融资历程成果显著:2023年3月，Pathos初获2000万美元风险投资资金，这笔启动资金为公司早期技术研发、团队搭建及数据平台初步建设筑牢根基，助力其在AI制药赛道崭露头角。2024年10月，Pathos完成由新企业协会（NEA）领投的6200万美元C轮融资，Revolution Growth、Lightbank和Builders VC等跟投，融资后估值6亿美元，使公司总融资达到1.02亿美元。资金主要用于扩大世界级科学家与工程师团队规模，加速人工智能药物开发平台的深入研发，全力推进精准肿瘤治疗临床阶段管线进展，为后续业务拓展与技术突破蓄势。今年，Pathos刚刚完成3.65亿美元D轮融资，在当前全球资本市场环境趋紧的背景下，能获得如此大规模的融资，恰恰表明投资者对Pathos开发的AI驱动的肿瘤药物开发模式充满信心。02核心技术平台PathOS三大优势，覆盖药物开发全流程在全球生物制药市场中，肿瘤学是增长最快的细分领域之一。Pathos的专有平台PathOS Platform是一个专为肿瘤学设计的AI基础模型（AI Foundation Model），其核心竞争力源于对肿瘤领域的深度聚焦与技术创新。通过多模态时空数据整合和AI算法建模驱动，Pathos利用PathOS Platform实现对癌细胞的高通量筛选以及个性化预测，并将经过AI模型预测的靶点用于临床试验设计，以三大差异化优势实现从靶点发现到临床落地的全流程覆盖：Pathos AI概念图来自：Pathos官网● PB级多模态数据整合，构建肿瘤研究数据基座PathOS Platform整合了PB级（Petabyte，拍字节）的多模态肿瘤数据集，覆盖临床诊疗、功能基因组与影像学数据，且数据均源自真实世界的肿瘤患者诊疗过程。这类多维度数据融合打破了单一数据类型的局限，能更精准捕捉肿瘤异质性，反映肿瘤疾病的特征。相比传统单一类型的数据，该多模态数据集为AI模型提供了更丰富的训练素材，使其在靶点发现、患者反应预测及临床试验设计中具备更强的分析能力。● 自学习Discovery Engine，动态优化研发流程PathOS Platform搭载的自学习和自修复发现引擎，可通过多种正交方法自动识别并排序药物靶点，并基于新数据实时修正预测模型。例如，当临床试验中出现新的疗效数据时，引擎会自动调整靶点优先级，避免人工干预的滞后性。同时，该引擎还能整合从靶点发现到临床试验的全链条数据，确保研发各环节的一致性与连贯性，有助于持续优化药物研发流程。● 因果AI框架，从相关性分析到机制预测的突破区别于传统AI的相关性分析，Pathos的因果AI框架能够直击药物作用的核心生物学机制，通过推理药物-靶点-疗效的因果链条，能够更精准地把握药物作用机制与患者疗效之间的关系，精准预测患者对疗法的响应概率。这一技术路径可提高临床成功率，减少盲目尝试，降低肿瘤药物研发中常见的高失败率。由此可看出，PathOS Platform通过三大技术支持，从药物靶点发现到临床试验设计和患者选择，全面覆盖药物开发全流程。其先进的AI算法可同步优化患者选择、生物标志物开发与试验操作，使药物开发更加精准和高效。这种数据-算法-临床的模式，不仅加速了药物临床流程，更推动肿瘤治疗向精准化、个性化迈进，成为Pathos在肿瘤AI制药领域的核心竞争力。03两条临床管线进展迅速，正在攻克多种肿瘤难题目前，Pathos拥有两条临床管线药物——Pocenbrodib和P-500。关键是，这两条管线都来自外部授权，而Pathos发挥其关键优势——依托PathOS Platform因果AI模型，加速推进管线临床进程，同时为其模型平台积累数据、形成侧面印证。其中，Pocenbrodib是Pathos于2023年从诺和诺德手中获得全球许可权，该药物最初由Forma Therapeutics（专注于癌症治疗的生物制药公司）研发；而P-500是Pathos在2024年从Prelude Therapeutics（专注于精准肿瘤学的生物制药公司）处取得许可。Pathos的研发管线来自：Pathos官网● Pocenbrodib：靶向前列腺癌及多种实体瘤的小分子抑制剂前列腺癌作为男性高发恶性肿瘤，其晚期阶段转移性去势抵抗性前列腺癌（mCRPC）一直是临床治疗的难点。患者在经历去势治疗后，肿瘤依然会继续生长和转移，而传统抗雄激素治疗手段常因癌细胞中雄激素受体（AR）及其变体的持续激活而失效，导致治疗选择极为有限。数据显示，mCRPC患者平均总生存期仅为13-36个月，且现有治疗手段对肿瘤细胞的抑制效果逐渐减弱，耐药性成为治疗的一大阻碍，患者生存率和生活质量难以得到有效保障，亟待机制创新的疗法打破耐药困局。Pocenbrodib（以前称为FT-7051）作为一种小分子抑制剂，通过靶向抑制CREBBP/EP300（即CBP/P300）发挥作用。CBP/P300是激活促进癌细胞生长和增殖的基因的蛋白质，这类蛋白质在激活促进癌细胞生长和增殖的基因过程中扮演着重要角色，可通过促进AR及其变体的表达驱动肿瘤增殖。当Pocenbrodib抑制这些蛋白质活性后，关键癌症驱动因素的表达，包括AR及其变体均受到影响。这一作用机制使得癌细胞的生长和增殖受到抑制，不仅对晚期前列腺癌治疗意义重大，而且为其他多种实体瘤的治疗开辟了新途径，无论是单独使用还是与其他治疗手段联合，都具有潜在的临床价值。2025年3月，Pathos运用AI基础模型启动了Pocenbrodib的1b/2a期临床试验。该试验将评估其单药疗法，以及与 Zytiga（阿比特龙）、Lynparza（奥拉帕利）或 Pluvicto（镥氧奥曲肽）联合用药的安全性、药代动力学及初步抗肿瘤活性，为后续临床阶段提供关键数据。● P-500：突破血脑屏障，直击脑瘤的创新疗法高级别胶质瘤是最常见的原发性颅内恶性肿瘤，具有侵袭性强、易复发、预后差等特点。葡萄膜黑色素瘤是成年人最常见的眼内恶性肿瘤，部分患者会发生转移，尤其是向脑部转移，严重威胁患者生命健康。这两类脑肿瘤由于肿瘤位置特殊，治疗难度极大。在针对脑瘤的传统疗法中，血脑屏障（BBB）的存在使得许多药物难以进入脑部发挥作用，脑肿瘤的治疗药物选择受限。且高级别胶质瘤和葡萄膜黑色素瘤的癌细胞生长和扩散迅速，现有治疗手段难以有效控制病情发展，患者生存时间短，生活质量严重下降。P-500 (以前称为PRT811) 是一款专为脑肿瘤设计的蛋白质精氨酸甲基转移酶5 (PRMT5) 的选择性小分子抑制剂。PRMT5作为调控细胞增殖与RNA剪接的关键酶，能够利用S-腺苷甲硫氨酸（SAM）将甲基添加到细胞中的蛋白质上，进而调节蛋白质的功能和相互作用。而支持癌细胞生长和扩散的多个过程都依赖于PRMT5。P-500通过抑制PRMT5，干扰癌细胞生长和扩散相关的关键过程，从而发挥抗肿瘤作用。此外，临床前研究表明，PRMT5抑制可以使癌细胞对其他治疗更为敏感，从而将P-500的应用扩展到其他适应症的联合治疗。目前，P-500正在进行针对实体瘤（包括高级别胶质瘤和葡萄膜黑色素瘤）的1期临床试验，Pathos计划在2025年启动该药物的进一步临床试验，有望为晚期实体瘤尤其是脑肿瘤患者带来新的生机。04与阿斯利康、Tempus AI达成合作，聚焦肿瘤药物研发2025年4月23日，Pathos宣布与全球生物制药巨头阿斯利康、头部AI医疗公司Tempus AI（AI检测检验及数据服务）达成多年期战略合作，三方将联合构建肿瘤学多模态基础模型，通过数据共享与技术协同开发新型药物研发模式。其中，与阿斯利康的合作有助于Pathos利用其在肿瘤研发领域的丰富经验和资源，共同推进肿瘤药物的研发；与Tempus AI的合作则为Pathos提供了大量的高质量数据和先进的AI技术支持。这一合作标志着AI制药企业与传统药企、医疗数据平台的深度融合，也反映出当前医疗行业融合发展的竞争新态势。从行业大背景看，AI制药正处于快速发展期。《2025年AI制药市场分析及未来发展趋势报告》显示，2025年全球AI制药市场规模预计达200亿美元，年复合增长率超30%，超过百家初创公司和大型制药企业已布局该领域。AI技术的应用已从早期的药物分子设计，延伸至靶点发现、临床试验优化等全链条环节。事实上，AI在制药行业的渗透已突破技术应用的单一维度，而正深刻改变企业运营、商业模式乃至整个产业生态格局。对于整个医疗行业而言，AI不再仅是提升研发效率的工具，更会在未来持续推动产业形态与价值链的重塑。在这一深刻转型中，Pathos AI能否洞察趋势、精准应用AI优势并通过跨企业资源整合加速创新效率，更快速地为药物研发注入强大动力，进而在肿瘤药物研发领域树立新的行业标准，或许未来在其临床试验数据中会找到答案。如果您想对接文章中提到的项目，或您的项目想被动脉网报道，或者发布融资新闻，请与我们联系；也可加入动脉网行业社群，结交更多志同道合的好友。近期推荐声明：动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。未经许可，禁止进行转载、摘编、复制及建立镜像等任何使用。文中如果涉及企业信息和数据，均由受访者向分析师提供并确认。动脉网，未来医疗服务平台

2025-05-15

·FierceBiotech

Pathos AI secures $365M series D to fund trial of Novo Nordisk solid tumor drug

In addition to funding its clinical work, Pathos AI stated that this morning’s series D would be used to further invest in its artificial intelligence platform.\n Pathos AI has secured $365 million in a series D raise as the artificial-intelligence-powered biotech looks to fund trials of solid tumor drugs sourced from Novo Nordisk and Prelude Therapeutics.The company can now lay claim to a post-money valuation of around $1.6 billion, according to a May 15 release. At the top of Pathos’ spending priorities is advancing its clinical-stage pipeline, which is led by pocenbrodib.The Boston-based biotech licensed the CBP/p300 inhibitor program in 2023 from Novo Nordisk, where the med was in phase 1 development for prostate cancer. When it acquired the drug, which has origins at Forma Therapeutics, Pathos said pocenbrodib had the potential to work against multiple other tumor types.In March, Pathos launched its own phase 1b/2a trial of pocenbrodib as a monotherapy and in combination with Zytiga, Lynparza or Pluvicto in patients with metastatic castration-resistant prostate cancer.The company told Fierce Biotech on Thursday that its other “key priority” this year is to launch a trial of P-500, a brain-penetrant PRMT5 inhibitor licensed from Prelude Therapeutics in 2024. Prelude had been assessing the drug in a phase 1 trial of patients with solid tumors, including high-grade glioma and uveal melanoma.In both cases, Pathos’ strategy is to use its PathOS Platform to identify biomarkers that could help pinpoint patient populations that would most benefit from these clinical-stage drugs.Pathos also took ownership of the phase 3-stage MDM2 inhibitor milademetan as part of its acquisition of Rain Oncology in December 2023. However, Pathos hasn’t name-checked the failed liposarcoma therapy in its more recent releases.In addition to funding its clinical work, Pathos stated that this morning’s series D would be used to further invest in its AI platform to “drive greater speed, precision and success in oncology drug development.” The next phase of work on the platform involves drawing together clinical, molecular and imaging data to help improve the selection of clinical assets and oncology biomarkers as well as to improve trial designs.“Pathos was founded to transform drug development by harnessing the full potential of multimodal data and AI,” said Iker Huerga, who took over as CEO of the biotech last week.“With this financing, we’re building one of the most advanced AI engines, designed to accelerate development, deepen clinical insight, and ensure the right therapies reach the patients who need them most,” added Huerga, who most recently served as chief data scientist for oncology R&D at AstraZeneca.Thursday\'s release didn’t include the identities of the participants in the series D round. Pathos told Fierce Biotech the round included a mix of returning backers and fresh capital from new investors. The latest round comes just seven months after Pathos raised a $62 million series C led by New Enterprise Associates.

临床1期并购

100 项与 PRT-811 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
高级别胶质瘤	临床2期	-	Pathos	-
葡萄膜黑色素瘤	临床2期	-	Pathos	-
晚期恶性实体瘤	临床1期	美国	Prelude Therapeutics, Inc.	2019-11-06
原发性中枢神经系统淋巴瘤	临床1期	美国	Prelude Therapeutics, Inc.	2019-11-06
复发性胶质瘤	临床1期	美国	Prelude Therapeutics, Inc.	2019-11-06

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04089449 (GlobeNewswire) 人工标引	临床1期	晚期恶性实体瘤	86	P-500 (previously PRT811)	醖夢憲願選選憲範願積(鹹廠襯醖夢築選窪憲簾) = the most common adverse events of any grade, with an incidence of >20% were nausea (60.5%), vomiting (46.5%) fatigue (36.0%), constipation (29.1%), and thrombocytopenia (24.4%), and were predominantly grade 1-2. 鹽衊夢糧夢糧構齋衊顧 (觸獵觸糧壓鬱選艱蓋選 ) 更多	积极	2024-08-15
NCT04089449 (GlobeNewswire) 人工标引	临床1期	晚期恶性实体瘤	86	P-500 (previously PRT811) (high-grade glioma with isocitrate dehydrogenase mutations (IDH+))		积极	2024-08-15
NCT04089449 (ASCO 12023 \| ASCO 22023) 人工标引	临床1期	葡萄膜黑色素瘤 \| 复发性恶性胶质瘤	61	PRT811	簾築齋窪遞積築鏇膚選(鹽顧鹹齋齋壓憲壓醖網) = 600 mg QD and 19 pts received between 15 to 800 mg PRT811 QD 築壓鏇遞簾鹽選淵艱製 (網積築範夢齋積鏇蓋選 ) 更多	积极	2023-05-26
NCT04089449 (AACR2021) 人工标引	临床1期	HR阳性/HER2低表达实体瘤 \| 复发性恶性胶质瘤	38	PRT811	窪顧膚鏇顧繭糧鑰繭鬱(製鹹鹽遞網鏇觸鑰築鹽) = none 襯餘築繭襯構艱製簾鹽 (壓醖顧壓壓廠壓壓淵鏇 ) 更多	积极	2021-12-01
NCT04089449 (AACR2020)	临床1期	脑癌	86	PRT811	窪製鬱繭糧糧構膚膚齋(鬱壓簾餘艱簾構廠獵簾) = 襯製範獵觸齋鹹遞餘積壓鏇壓鏇觸獵淵鹽簾齋 (顧醖製觸餘簾繭廠壓艱 ) 更多	-	2020-08-15